不同剂型棕榈酸帕利哌酮治疗精神分裂症有效性及安全性分析

Comparative analysis of efficacy and safety of different dosage forms of paliperidone palmitate in the treatment of schizophrenia

目的 比较1个月注射1次的棕榈酸帕利哌酮注射液(PP1M)与3个月注射1次的棕榈酸帕利哌酮注射液(PP3M)在有效性和安全性方面的差异。方法 检索中国知网、万方数据知识服务平台、PubMed、Embase、the cochrane Library等数据库中关于PP1M与PP3M有效性及安全性比较研究的文献,检索时间为数据库建库至2023年11月。结果 共纳入10篇文献,研究对象均为成人精神分裂症患者,研究周期7~24个月。结果显示,PP1M和PP3M对于精神分裂症患者的症状改善程度相似,PP3M比PP1M更能降低因精神疾病住院率和疾病复发风险,使用PP3M发生锥体外系综合征和体质量增加的风险低于PP1M,其他安全性指标在二者之间没有明显区别。结论 PP1M和PP3M的疗效与安全性相当,PP3M用药依从性更好。

Objective To compare the difference in efficacy and safety between paliperidone palmitate 1-month(PP1M) and paliperidone palmitate 3-month(PP3M).Methods A systematic review of the literature on the efficacy and safety of PP1M and PP3M in relevant Chinese and English databases from CNKI,Wanfang Data,PubMed,Embase,the Cochrane Library and so on,from the inception of the database until November,2023.Results A total of 10 literatures were further screened to meet the exclusion criteria.The subjects of the included literature were all adult schizophrenia patients with a study period ranging from 7 months to 24 months.The results showed that PP1M and PP3M improved the symptoms of patients with schizophrenia to a similar extent.PP3M was more effective than PP1M in reducing the rate of hospitalization for psychiatric disorders and the risk of relapse.The risk of extrapyramidal symptoms(EPS) and weight gain was lower with PP3M than with PP1M,and there was no significant difference in other safety indexes between the two groups.Conclusion The efficacy and safety of PP1M and PP3M were comparable,and the medication compliance of PP3M was better.